Drug Combination Details
| General Information of the Combination (ID: C26124) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Bacillus Calmette-Guerin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CD83 | Molecule Info | ||
| Up-regulation | Expression | FUN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | GABPA | Molecule Info | |||
| Down-regulation | Expression | IER3 | Molecule Info | |||
| Up-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NQO1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | ||
| In-vivo Model | 0.15 mL human bladder cancer cell suspension (with a concentration of 1 * 107 /ml) was injected through the catheter into the urinary bladder cavity. | |||||
| Experimental
Result(s) |
Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway. | |||||
